Horizon Therapeutics Opposes Centralization of Tepezza Infusion Lawsuits in MDL
Plaintiffs say identical facts, injuries and legal arguments make the Tepezza infusion lawsuits ripe for consolidation as part of a multidistrict litigation.
Plaintiffs say identical facts, injuries and legal arguments make the Tepezza infusion lawsuits ripe for consolidation as part of a multidistrict litigation.
The Tepezza lawsuit claims the manufacturer knew about the risk of hearing loss side effects, but failed to warn patients and the medical community
At least 18 Tepezza lawsuits over hearing loss are pending in multiple federal courts nationwide, and the number of claims is expected to continue to grow
Plaintiff indicates the Tepezza hearing injury came after she received several infusions of the thyroid eye disease drug.
The updated Tepezza label could significantly expand use of the thyroid eye disease treatment, even as lawsuits are being pursued over failure to warn about the hearing damage risks
Lawsuit indicates that neither the plaintiff nor her doctors were warned that Tepezza infusions could cause hearing loss and tinnitus, which persists long after the thyroid eye disease treatments
Researchers indicate that a woman suffered both severe gastrointestinal problems and hearing loss from Tepezza, but the side effects resolved when the dosage was cut in half.
Lawsuits brought throughout the federal court system each involve similar allegations that Tepezza caused hearing problems, resulting in a request to centralize the cases in a Multidistrict Litigation (MDL)
Infusions of Tepezza caused hearing loss problems that were not disclosed by the drug maker, and could have been avoided if warnings about the importance of audiological monitoring had been provided, according to lawsuit.